Parexel and ASAN accelerate Korea-based drug development

Wednesday, February 1, 2012 03:33 PM

CRO Parexel International has joined with ASAN Medical Center (AMC), based in Seoul, Korea, to offer clinical trial sponsors based regionally and internationally access to clinical trial services throughout Asia, with a focus on early phase development.

“With ASAN Medical Center's leadership in clinical trials, in-depth expertise, state-of-the art facilities and a renowned network of hospitals, we believe our alliance will offer unique advantages to the Korean biopharmaceutical industry,” said Mark A. Goldberg, M.D., COO of Parexel. “We look forward to contributing to continued drug development growth in the region through shared learnings, technologies and best practices."

The AMC Clinical Trial Center, which opened in 2002, was designated as the Regional Clinical Trial Center by the Korean Ministry for Health, Welfare and Family Affairs in 2006. The government's investment made it possible for the center to rapidly build infrastructure. 

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs